TrialThe lancet. HIV2025

Statin effects on the incidence of major non-cardiovascular disease events among a global cohort of people with HIV: a randomised controlled trial.

Marissa R Diggs et al.PubMed ↗Full text ↗Publisher ↗

A later paper about NCT02344290. The trial’s primary report, PMID 37486775, speaks for it on the map; the numbers here are shown and do not vote.

Pitavastatin 4 mg dailyno clear effectNo clear effect on major non-CVD events.Nothing cleared the noise.

What the trial testedas reported · 7,769 people · 2025

Range includes no effect

No clear effect on major non-CVD events

Doesn’t vote: a later paper about the trial

−8%−24% to +13%

pitavastatin 4 mg daily vs placebo

Bigger than 3 in 10 for adverse events & safety

As reported

HR 0.92, 95% CI 0.76–1.13

Who was studied, and how

7,769people with cardiovascular disease, in this paper

The trial randomly assignedassigned by chance

pitavastatin 4 mg daily

placebo

No clear effect on major non-CVD events−8%

randomised

the abstract, start to end

… (hazard ratio [HR], cause-specific: 0.92, 95% CI 0.76-1.13; p=0.44).

← favours treatmentfavours comparator →

could be chance

Major non-CVD events (including AIDS-defining events, non-AIDS-defining cancers, renal disease, and liver disease)pitavastatin 4 mg daily vs placebo

HR 0.920.76–1.13

StatinsAdverse events & safety

1 / 4

1 paper cites it

2025

2026

this papertrialcites it

The trial

NCT02344290phase 37,769 enrolled2015a later paper about it

Statin effects on the incidence of major non-cardiovascular disease events among a global cohort of people with HIV: a randomised controlled trial.

What the trial testedas reported · 7,769 people · 2025

No clear effect on major non-CVD events

Who was studied, and how

One number in the abstract

Where each one falls

Where it lands on the map

1 paper cites it

The trial